Quantitative imaging of receptor‐ligand engagement in intact live animals

ABSTRACT Maintaining an intact tumor environment is critical for quantitation of receptor‐ligand engagement in a targeted drug development pipeline. However, measuring receptor‐ligand engagement in vivo and non‐invasively in preclinical settings is extremely challenging. We found that quantitation of intracellular receptor‐ligand binding can be achieved using whole‐body macroscopic lifetime‐based Förster Resonance Energy Transfer (FRET) imaging in intact, live animals bearing tumor xenografts. We determined that FRET levels report on ligand binding to transferrin receptors conversely to raw fluorescence intensity. FRET levels in heterogeneous tumors correlate with intracellular ligand binding but strikingly, not with ubiquitously used ex vivo receptor expression assessment. Hence, MFLI‐FRET provides a direct measurement of systemic delivery, target availability and intracellular drug delivery in preclinical studies. Here, we have used MFLI to measure FRET longitudinally in intact and live animals. MFLI‐FRET is well–suited for guiding the development of targeted drug therapy in heterogeneous tumors in intact, live small animals. Graphical abstract Figure. No caption available.

[1]  Miles A. Miller,et al.  Advances in measuring single-cell pharmacology in vivo. , 2015, Drug discovery today.

[2]  Xavier Intes,et al.  Active wide-field illumination for high-throughput fluorescence lifetime imaging. , 2013, Optics letters.

[3]  P. Low,et al.  In vivo mouse fluorescence imaging for folate-targeted delivery and release kinetics , 2014, Biomedical optics express.

[4]  Gustavo Helguera,et al.  The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. , 2006, Clinical immunology.

[5]  Neil O Carragher,et al.  Intravital FLIM-FRET imaging reveals dasatinib-induced spatial control of src in pancreatic cancer. , 2013, Cancer research.

[7]  Tayyaba Hasan,et al.  Microscopic lymph node tumor burden quantified by macroscopic dual-tracer molecular imaging , 2014, Nature Medicine.

[8]  Xavier Intes,et al.  FLIM-FRET for Cancer Applications. , 2015, Current molecular imaging.

[9]  T. Reiner,et al.  Direct Imaging of Drug Distribution and Target Engagement of the PARP Inhibitor Rucaparib , 2018, The Journal of Nuclear Medicine.

[10]  Hongzhe Sun,et al.  Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway , 2002, Pharmacological Reviews.

[11]  F. Wouters,et al.  Fluorescence lifetime imaging microscopy in the medical sciences , 2014, Protoplasma.

[12]  Xavier Intes,et al.  Comparison of illumination geometry for lifetime‐based measurements in whole‐body preclinical imaging , 2018, Journal of biophotonics.

[13]  Tayyaba Hasan,et al.  Quantitative in vivo immunohistochemistry of epidermal growth factor receptor using a receptor concentration imaging approach. , 2014, Cancer research.

[14]  R. Duran,et al.  Mapping of drug distribution in the rabbit liver tumor model by complementary fluorescence and mass spectrometry imaging , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[15]  Valerie Speirs,et al.  Choosing the right cell line for breast cancer research , 2011, Breast Cancer Research.

[16]  Xavier Intes,et al.  AlliGator: A Phasor Computational Platform for Fast in vivo Lifetime Analysis. , 2017, Optical molecular probes, imaging and drug delivery.

[17]  C. Lok,et al.  Identification of a Hypoxia Response Element in the Transferrin Receptor Gene* , 1999, The Journal of Biological Chemistry.

[18]  Jürgen Wolfrum,et al.  How many photons are necessary for fluorescence-lifetime measurements? , 1992 .

[19]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[20]  A. Mason,et al.  Endosome–mitochondria interactions are modulated by iron release from transferrin , 2016, The Journal of cell biology.

[21]  Edward H. Kerns,et al.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.

[22]  F. Kiessling,et al.  Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Xavier Intes,et al.  Compressive hyperspectral time-resolved wide-field fluorescence lifetime imaging. , 2017, Nature photonics.

[24]  Xavier Intes,et al.  Development of an optical imaging platform for functional imaging of small animals using wide-field excitation , 2010, Biomedical optics express.

[25]  Borivoj Vojnovic,et al.  HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status , 2016, Oncotarget.

[26]  Margarida M Barroso,et al.  Quantum dots as fluorescence resonance energy transfer donors in cells. , 2008, Journal of biomedical optics.

[27]  Jason S. Lewis,et al.  Noninvasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared with 18F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer , 2018, The Journal of Nuclear Medicine.

[28]  Jason S. Lewis,et al.  Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin , 2016, Clinical Cancer Research.

[29]  Michael F. Cuccarese,et al.  Quantitating drug-target engagement in single cells in vitro and in vivo. , 2017, Nature chemical biology.

[30]  M. Jong,et al.  Imaging preclinical tumour models: improving translational power , 2014, Nature Reviews Cancer.

[31]  Sophie J Deharvengt,et al.  Dynamic dual-tracer MRI-guided fluorescence tomography to quantify receptor density in vivo , 2013, Proceedings of the National Academy of Sciences.

[32]  Wolfgang A. Weber,et al.  Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging , 2007, Proceedings of the National Academy of Sciences.

[33]  Xavier Intes,et al.  Quantitative tomographic imaging of intermolecular FRET in small animals , 2012, Biomedical optics express.

[34]  Dietmar W. Siemann,et al.  Modulation of the tumor vasculature and oxygenation to improve therapy. , 2015, Pharmacology & therapeutics.

[35]  G. Bonamy,et al.  Receptor complexes cotransported via polarized endocytic pathways form clusters with distinct organizations. , 2007, Molecular biology of the cell.

[36]  M. Blanco,et al.  Target engagement in lead generation. , 2015, Bioorganic & medicinal chemistry letters.

[37]  Xavier Intes,et al.  Assessment of Gate Width Size on Lifetime-Based Förster Resonance Energy Transfer Parameter Estimation , 2015, 2015 41st Annual Northeast Biomedical Engineering Conference (NEBEC).

[39]  H. Fuchs,et al.  Iodination significantly influences the binding of human transferrin to the transferrin receptor. , 2002, Biochimica et biophysica acta.

[40]  N. Sunaga,et al.  Metabolic activity by 18F–FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[41]  B. Cravatt,et al.  Determining target engagement in living systems. , 2013, Nature chemical biology.

[42]  X. Intes,et al.  Temporal Data Set Reduction Based on D-Optimality for Quantitative FLIM-FRET Imaging , 2015, PloS one.

[43]  Jason S. Lewis,et al.  Annotating MYC oncogene status with 89Zr-transferrin imaging , 2012, Nature Medicine.

[44]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[45]  Xavier Intes,et al.  Non-Invasive In Vivo Imaging of Near Infrared-labeled Transferrin in Breast Cancer Cells and Tumors Using Fluorescence Lifetime FRET , 2013, PloS one.

[46]  W. Willmore,et al.  Regulation of iron pathways in response to hypoxia. , 2011, Free radical biology & medicine.

[47]  Xavier Intes,et al.  Spatial light modulator based active wide-field illumination for ex vivo and in vivo quantitative NIR FRET imaging. , 2014, Biomedical optics express.

[48]  Paul M. Matthews,et al.  Positron emission tomography molecular imaging for drug development. , 2012, British journal of clinical pharmacology.

[49]  Simon R. Arridge,et al.  In vivo fluorescence lifetime tomography of a FRET probe expressed in mouse , 2011, Biomedical optics express.

[50]  B. Hann,et al.  Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer , 2017, Molecular Cancer Research.